SlideShare a Scribd company logo
“Sequelae at hospital discharge in 49 children
with invasive meningococcal disease. Chile,
2009-2019”.
november 2021
Cindy Arteta (1,2), Rodolfo Villena (1,3), María Elena Santolaya (1,2)
1. Faculty of Medicine Universidad de Chile, 2. Hospital de niños Dr Luis Calvo Mackenna 3. Hospital de
niños Dr Exequiel González Cortés
Contact: Rodolfo Villena. rvillena@uchile.cl
• Introduction
• “Defeating meningitis by 2030” is a goal of the World Health Organization
• To address the sequelae is one of the pillar for it
• Chilean study: overall IMD sequelae rate of 28% (MenB outbreak in 90s)
• Objective
• Describe the sequelae caused by IMD in pediatric patients
• Methods
• Cross-sectional study performed with medical records in two pediatric public
hospitals in Santiago, Chile
• Patients with diagnosis of IMD from 2009-2019 microbiologically confirmed were
included
• Bivariate analysis and logistic regression were performed
“Sequelae at hospital discharge in 49 children with
invasive meningococcal disease. Chile, 2009-2019”
Table 1. Socio-demographic data of children with IMD, Chile, 2009-2019
79,5%
98%
“Sequelae at hospital discharge in 49 children with
invasive meningococcal disease. Chile, 2009-2019”
Variables Total n=49 (%) Sequelae n=29 (%)
59%
No sequelae n=20 (%) p value
Age Median [IQR],
months
9 [4-27] 8.0 [4-23] 12.0 [4-82]
< 1 year old 28 (57.1) 18 (62.0) 10 (50.0) 0.40
1-4 years old 11 (22.4) 7 (24.1) 4 (20.0) 0.74
>5 years old 10 (20.4) 4 (13.7) 6 (30.0) 0.14
Gender Male 34 (69.3) 19 (65.5) 15 (75.0) 0.45
Socioeconomic
status
High 1 (2.0) 1 (3.4) 0 0.40
Middle 26 (53.0) 12 (41.3) 14 (70.0) 0.04
Low 22 (44.9) 16 (55.1) 6 (30.0) 0.08
Comorbidity Yes 16 (32.6) 9 (31.0) 7 (35.0) 0.76
Type of
comorbidity
Recurrent wheezing 9 (18.3) 5 (17.2) 4 (20.0) 0.78
Immunodeficiency 2 (4.0) 1 (3.4) 1 (5.0) 0.78
Prematurity 2 (4.0) 2 (6.9) 0 0.26
Neurological
disease
1 (2.0) 0 1 (5.0) 0.22
Congenital
cardiopathy
1 (2.0) 0 1 (5.0) 0.22
Obesity 4 (8.1) 3 (10.3) 1 (5.0) 0.52
Malnutrition 2 (4.0) 1 (3.4) 1 (5.0) 0.78
Results
Univariate Associations Logistic Regression analysis
Variable Total N 49 (%) Sequelae N 29
(%)
No sequelae 20
(%)
p value OR 95% CI
Onset of
symptoms before
consulting (days)
Median [IQR] 2.0 [1.0-4.0] 2.0 [1.0-3.0] 2.0 [1.0-3.0] 1 - -
Number of
medical visits
1 11 (22.4) 8 (27.5) 3 (15.0) 0.31
2 27 (55.1) 15 (51.7) 12 (60.0) 0.56
>3 11 (22.4) 6 (20.6) 5 (25.0) 0.67
Signs and
symptoms
Fever 49 (100) 29 (100) 20 (100) 1
Compromised general
condition
36 (73.4) 23 (79.3) 13 (65.0) 0.26 0.28 (0.03 – 2.56)
Shock 25 (51.0) 8 (27.5) 3 (15.0) 0.03 2.15 (0.49 – 9.41)
Vomiting 31 (63.2) 16 (55.1) 15 (75.0) 0.01 17.06 (1.74 – 166.94)
Diarrhea 14 (28.5) 8 (27.5) 6 (30.0) 0.84 1.62 (0.23 – 11.40)
Abdominal pain 6 (12.2) 2 (6.9) 4 (20.0) 0.16 0.29 (0.04 – 1.80)
Drowsiness/irritability 23 (46.9) 17 (58.6) 7 (35.0) 0.10 2.83 (0.39 – 20.44)
Meningeal signs 21 (42.8) 17 (58.6) 4 (20.0) 0.007 0.04 (0.00 – 0.55)
Neurological deficit 20 (40.8) 16 (55.1) 4 (20.0) 0.2 0.34 (0.07 – 1.56)
Headache 14 (28.5) 10 (34.4) 4 (20.0) 0.27 1.09 (0.16 – 7.28)
Seizures 3 (6.1) 2 (6.9) 1 (5.0) 0.78 - -
Petechiae/rash 20 (40.8) 12 (41.3) 8 (40.0) 0.92 0.66 (0.12 – 3.48)
Table 2. Clinical characteristics of invasive meningococcal disease by presents of sequelae in Chilean children during 2009-2019
Results
“Sequelae at hospital discharge in 49 children with invasive
meningococcal disease. Chile, 2009-2019”
Univariate Associations Logistic Regression analysis
Variable Total N 49 (%) Sequelae N 29 (%) No sequelae 20 (%) P value OR 95% CI
Clinical diagnosis Meningitis +
meningococcemia
19 (38.7) 17 (58.6) 2 (10.0) <0.001 12.75 (2.48 – 65.54)
Bacteremia 10 (20.4) 1 (3.4) 9 (45.0) <0.001 0.007 (0.00 – 0.21)
Septic arthritis 7 (14.2) 7 (24.1) 0 0.01
Meningitis 6 (12.2) 2 (6.9) 4 (20.0) 0.16 3.64 (0.31 – 41.65)
Meningococcemia 5 (10.2) 0 5 (25.0) 0.06 - -
Waterhouse
Friderichsen Syndrome
2 (4.0) 2 (6.9) 0 0.23 - -
Number of sequelae 1 19 (38.7) 19 (65.5) -
2 8 (16.3) 8 (27.5) -
3 2 (4.0) 2 (6.9) -
Type of sequelae* Neurological disorders 19 (38.7) 19 (65.5) -
Hearing loss 10 (20.0) 10 (34.4) -
Osteoarticular 9 (18.3) 9 (31.0) -
Skin scarring 3 (6.1) 3 (10.3) -
Post discharge
follow-up
Yes 34 (69) 27 (93.1) 7 (35.0) <0.001
N. meningitidis
serogroup
B 17 (34.6) 11 (37.9) 6 (30.0) 0.61
W 30 (61.2) 16 (55.1) 14 (70.0) 0.29
Table 2. Clinical characteristics of invasive meningococcal disease by presents of sequelae in Chilean children during 2009-2019
Results
“Sequelae at hospital discharge in 49 children with invasive
meningococcal disease. Chile, 2009-2019”
Table 3. Classification of sequelae in children with IMD
“Sequelae at hospital discharge in 49 children with
invasive meningococcal disease. Chile, 2009-2019”
Type of sequelae
Number of
sequelae: 54
%
Neurological disorders 32 59.2
Psychomotor developmental
delay
12 22.2
Speech-language
impairment
7 12.9
Seizures 5 9.2
Hypertonia/Hypotonia 5 9.2
Nerve damage 2 3.7
Attention deficit/
hyperactivity disorder
1 1.8
Hearing loss 10 18.5
Cochlear implant 2 3.7
Skin scarring 3 5.5
Osteoarticular 9 16.6
Movement limitation 6 11.1
Surgical debridement 2 3.7
Amputation 1 1.8
53%
27%
13%
7%
41%
18%
5%
36%
Sequelae of meningococcal disease by serogroup in Chilean children
Neurological
disorders
Hearing loss
Skin scarring
Osteoarticular
W
B
p 0.03
Figure 1. Sequelae of meningococcal disease by serogroup in chilean
children, 2009-2019
*
“Sequelae at hospital discharge in 49 children with
invasive meningococcal disease. Chile, 2009-2019”
2009-2013 2015-2019
Total 41 8
B 13 4
W 26 4
0
5
10
15
20
25
30
35
40
45
Cases
Sequelae by serogroup and time interval in peadiatrics
patients, Chile 2009-2019
p < 0.0001
*
*
*
• Invasive meningococcal disease remains as a public health concern
• A high rate of sequelae were found in pediatric patients in Chile (59%)
• Focus in < 1 yoa, shock and meningeal signs at admission
• Clinical manifestations: meningitis + meningococcemia
• Neurological sequelae were the most prevalent
• A multidisciplinary follow-up protocols to reduce their long-term impact
must be urgently established as a priority to assess all children and their
families with the aim to reduce the long-term consequences/impact of
IMD
Conclusions
“Sequelae at hospital discharge in 49 children with
invasive meningococcal disease. Chile, 2009-2019”
“Sequelae at hospital discharge in 49 children
with invasive meningococcal disease. Chile,
2009-2019”.
november 2021
Cindy Arteta (1,2), Rodolfo Villena (1,3), María Elena Santolaya (1,2)
1. Faculty of Medicine Universidad de Chile, 2. Hospital de niños Dr Luis Calvo Mackenna 3. Hospital de
niños Dr Exequiel González Cortés
Contact: Rodolfo Villena. rvillena@uchile.cl

More Related Content

What's hot

Potential use of MenABCWY vaccines
Potential use of MenABCWY vaccinesPotential use of MenABCWY vaccines
Potential use of MenABCWY vaccines
Meningitis Research Foundation
 
Dr Caroline trotter
Dr Caroline trotterDr Caroline trotter
Dr Caroline trotter
Meningitis Research Foundation
 
Yangyupei yang
Yangyupei yangYangyupei yang
Professor David goldblatt
Professor David goldblattProfessor David goldblatt
Professor David goldblatt
Meningitis Research Foundation
 
Dr Xin wang
Dr Xin wangDr Xin wang
Professor Sir Andrew Pollard
Professor Sir Andrew PollardProfessor Sir Andrew Pollard
Professor Sir Andrew Pollard
Meningitis Research Foundation
 
Professor Stefan flasche
Professor Stefan flascheProfessor Stefan flasche
Professor Stefan flasche
Meningitis Research Foundation
 
Dr Sami gottlieb
Dr Sami gottliebDr Sami gottlieb
Prof Rob Heyderman
Prof Rob HeydermanProf Rob Heyderman
Prof Rob Heyderman
Meningitis Research Foundation
 
Helen Campbell @ MRF's Meningitis & Septicaemia in Children & Adults 2017
Helen Campbell @ MRF's Meningitis & Septicaemia in Children & Adults 2017Helen Campbell @ MRF's Meningitis & Septicaemia in Children & Adults 2017
Helen Campbell @ MRF's Meningitis & Septicaemia in Children & Adults 2017
Meningitis Research Foundation
 
Brenda kwambana adams
Brenda kwambana adamsBrenda kwambana adams
Brenda kwambana adams
Meningitis Research Foundation
 
Claire Wright @ MRF's Meningitis and Septicaemia 2019
Claire Wright @ MRF's Meningitis and Septicaemia 2019  Claire Wright @ MRF's Meningitis and Septicaemia 2019
Claire Wright @ MRF's Meningitis and Septicaemia 2019
Meningitis Research Foundation
 
Dr Lee hampton
Dr Lee hamptonDr Lee hampton
Professor Cal MacLennan
Professor Cal MacLennanProfessor Cal MacLennan
Professor Cal MacLennan
Meningitis Research Foundation
 
Dr Anna Seale @ MRF's Meningitis and Septicaemia 2019
Dr Anna Seale @ MRF's Meningitis and Septicaemia 2019Dr Anna Seale @ MRF's Meningitis and Septicaemia 2019
Dr Anna Seale @ MRF's Meningitis and Septicaemia 2019
Meningitis Research Foundation
 
Dr Kirsty Le Doare @ MRF's Meningitis & Septicaemia
Dr Kirsty Le Doare @ MRF's Meningitis & Septicaemia Dr Kirsty Le Doare @ MRF's Meningitis & Septicaemia
Dr Kirsty Le Doare @ MRF's Meningitis & Septicaemia
Meningitis Research Foundation
 
Dr Matt Coldiron @ MRF's Meningitis and Septicaemia
Dr Matt Coldiron @ MRF's Meningitis and SepticaemiaDr Matt Coldiron @ MRF's Meningitis and Septicaemia
Dr Matt Coldiron @ MRF's Meningitis and Septicaemia
Meningitis Research Foundation
 
Prof James Stuart @ MRF's Meningitis & Septicaemia in Children & Adults 2017
Prof James Stuart @ MRF's Meningitis & Septicaemia in Children & Adults 2017Prof James Stuart @ MRF's Meningitis & Septicaemia in Children & Adults 2017
Prof James Stuart @ MRF's Meningitis & Septicaemia in Children & Adults 2017
Meningitis Research Foundation
 
Prof David Goldblatt @ Meningitis & Septicaemia in Children & Adults 2017
Prof David Goldblatt @ Meningitis & Septicaemia in Children & Adults 2017Prof David Goldblatt @ Meningitis & Septicaemia in Children & Adults 2017
Prof David Goldblatt @ Meningitis & Septicaemia in Children & Adults 2017
Meningitis Research Foundation
 
Dr Adam dale
Dr Adam daleDr Adam dale

What's hot (20)

Potential use of MenABCWY vaccines
Potential use of MenABCWY vaccinesPotential use of MenABCWY vaccines
Potential use of MenABCWY vaccines
 
Dr Caroline trotter
Dr Caroline trotterDr Caroline trotter
Dr Caroline trotter
 
Yangyupei yang
Yangyupei yangYangyupei yang
Yangyupei yang
 
Professor David goldblatt
Professor David goldblattProfessor David goldblatt
Professor David goldblatt
 
Dr Xin wang
Dr Xin wangDr Xin wang
Dr Xin wang
 
Professor Sir Andrew Pollard
Professor Sir Andrew PollardProfessor Sir Andrew Pollard
Professor Sir Andrew Pollard
 
Professor Stefan flasche
Professor Stefan flascheProfessor Stefan flasche
Professor Stefan flasche
 
Dr Sami gottlieb
Dr Sami gottliebDr Sami gottlieb
Dr Sami gottlieb
 
Prof Rob Heyderman
Prof Rob HeydermanProf Rob Heyderman
Prof Rob Heyderman
 
Helen Campbell @ MRF's Meningitis & Septicaemia in Children & Adults 2017
Helen Campbell @ MRF's Meningitis & Septicaemia in Children & Adults 2017Helen Campbell @ MRF's Meningitis & Septicaemia in Children & Adults 2017
Helen Campbell @ MRF's Meningitis & Septicaemia in Children & Adults 2017
 
Brenda kwambana adams
Brenda kwambana adamsBrenda kwambana adams
Brenda kwambana adams
 
Claire Wright @ MRF's Meningitis and Septicaemia 2019
Claire Wright @ MRF's Meningitis and Septicaemia 2019  Claire Wright @ MRF's Meningitis and Septicaemia 2019
Claire Wright @ MRF's Meningitis and Septicaemia 2019
 
Dr Lee hampton
Dr Lee hamptonDr Lee hampton
Dr Lee hampton
 
Professor Cal MacLennan
Professor Cal MacLennanProfessor Cal MacLennan
Professor Cal MacLennan
 
Dr Anna Seale @ MRF's Meningitis and Septicaemia 2019
Dr Anna Seale @ MRF's Meningitis and Septicaemia 2019Dr Anna Seale @ MRF's Meningitis and Septicaemia 2019
Dr Anna Seale @ MRF's Meningitis and Septicaemia 2019
 
Dr Kirsty Le Doare @ MRF's Meningitis & Septicaemia
Dr Kirsty Le Doare @ MRF's Meningitis & Septicaemia Dr Kirsty Le Doare @ MRF's Meningitis & Septicaemia
Dr Kirsty Le Doare @ MRF's Meningitis & Septicaemia
 
Dr Matt Coldiron @ MRF's Meningitis and Septicaemia
Dr Matt Coldiron @ MRF's Meningitis and SepticaemiaDr Matt Coldiron @ MRF's Meningitis and Septicaemia
Dr Matt Coldiron @ MRF's Meningitis and Septicaemia
 
Prof James Stuart @ MRF's Meningitis & Septicaemia in Children & Adults 2017
Prof James Stuart @ MRF's Meningitis & Septicaemia in Children & Adults 2017Prof James Stuart @ MRF's Meningitis & Septicaemia in Children & Adults 2017
Prof James Stuart @ MRF's Meningitis & Septicaemia in Children & Adults 2017
 
Prof David Goldblatt @ Meningitis & Septicaemia in Children & Adults 2017
Prof David Goldblatt @ Meningitis & Septicaemia in Children & Adults 2017Prof David Goldblatt @ Meningitis & Septicaemia in Children & Adults 2017
Prof David Goldblatt @ Meningitis & Septicaemia in Children & Adults 2017
 
Dr Adam dale
Dr Adam daleDr Adam dale
Dr Adam dale
 

Similar to Dr Rodolfo villena

Sickle Cell Disease: Newborn screening in France and the UK - Jacques Elion
Sickle Cell Disease: Newborn screening in France and the UK - Jacques ElionSickle Cell Disease: Newborn screening in France and the UK - Jacques Elion
Sickle Cell Disease: Newborn screening in France and the UK - Jacques Elion
Human Variome Project
 
Neonatal Meningitis
Neonatal MeningitisNeonatal Meningitis
Neonatal Meningitis
Meningitis Research Foundation
 
03_Challenge in diagnosis and management of dengue in adults_Dr. Terapong_11 ...
03_Challenge in diagnosis and management of dengue in adults_Dr. Terapong_11 ...03_Challenge in diagnosis and management of dengue in adults_Dr. Terapong_11 ...
03_Challenge in diagnosis and management of dengue in adults_Dr. Terapong_11 ...
surgeon8
 
Neonatal meningitis in the UK
Neonatal meningitis in the UKNeonatal meningitis in the UK
Neonatal meningitis in the UK
Meningitis Research Foundation
 
04.09.21 | Making Sense of the COVID-19 Data in Persons with HIV
04.09.21 | Making Sense of the COVID-19 Data in Persons with HIV04.09.21 | Making Sense of the COVID-19 Data in Persons with HIV
04.09.21 | Making Sense of the COVID-19 Data in Persons with HIV
UC San Diego AntiViral Research Center
 
ANAS UMAR INTERNAL DEFENCE SLIDES.pptx
ANAS UMAR INTERNAL DEFENCE SLIDES.pptxANAS UMAR INTERNAL DEFENCE SLIDES.pptx
ANAS UMAR INTERNAL DEFENCE SLIDES.pptx
AuwalUmar13
 
DIAGNOSIS OF PEDIATRIC INFECTIOUS DISEASES
DIAGNOSIS OF PEDIATRIC INFECTIOUS DISEASESDIAGNOSIS OF PEDIATRIC INFECTIOUS DISEASES
DIAGNOSIS OF PEDIATRIC INFECTIOUS DISEASES
WAidid
 
20180522 - universal health coverage from quantity to quality
20180522 - universal health coverage  from quantity to quality 20180522 - universal health coverage  from quantity to quality
20180522 - universal health coverage from quantity to quality
R.O.C.Ministry of Health and Welfare
 
Prof Elizabeth Miller @ MRF's Meningitis & Septicaemia in Children & Adults 2015
Prof Elizabeth Miller @ MRF's Meningitis & Septicaemia in Children & Adults 2015Prof Elizabeth Miller @ MRF's Meningitis & Septicaemia in Children & Adults 2015
Prof Elizabeth Miller @ MRF's Meningitis & Septicaemia in Children & Adults 2015
Meningitis Research Foundation
 
Ahmed Samir Abd Elhafez.pptx
Ahmed Samir Abd Elhafez.pptxAhmed Samir Abd Elhafez.pptx
Ahmed Samir Abd Elhafez.pptx
AhmedSamir462624
 
05NTD 2022 - UPDATES IN VECTOR CONTROL IN MALAYSIA: What is new?
05NTD 2022 - UPDATES IN VECTOR CONTROL IN MALAYSIA:  What is new?05NTD 2022 - UPDATES IN VECTOR CONTROL IN MALAYSIA:  What is new?
05NTD 2022 - UPDATES IN VECTOR CONTROL IN MALAYSIA: What is new?
Institute for Clinical Research (ICR)
 
Mealesss Global Regional MR Elimination Overview
Mealesss Global Regional MR Elimination OverviewMealesss Global Regional MR Elimination Overview
Mealesss Global Regional MR Elimination Overview
LourduAnthoni1
 
Invasive meningococcal disease, Surveillance
Invasive meningococcal disease, Surveillance Invasive meningococcal disease, Surveillance
Invasive meningococcal disease, Surveillance
European Centre for Disease Prevention and Control
 
Impact of COVID-19 on High-risk Conditions and Associated Complications in a ...
Impact of COVID-19 on High-risk Conditions and Associated Complications in a ...Impact of COVID-19 on High-risk Conditions and Associated Complications in a ...
Impact of COVID-19 on High-risk Conditions and Associated Complications in a ...
University of Michigan Department of Emergency Medicine
 
AN MFA APPLICATION IN TUBERCULOSIS PREVALENCE ANALYSIS
AN MFA APPLICATION IN TUBERCULOSIS PREVALENCE ANALYSISAN MFA APPLICATION IN TUBERCULOSIS PREVALENCE ANALYSIS
AN MFA APPLICATION IN TUBERCULOSIS PREVALENCE ANALYSISChaoyi WU
 
Beyond safety mining and public health final
Beyond safety mining and public health finalBeyond safety mining and public health final
Beyond safety mining and public health final
Francesca Viliani
 
GetPersonalized! Estonian approach - from biobanking to precision medicine, A...
GetPersonalized! Estonian approach - from biobanking to precision medicine, A...GetPersonalized! Estonian approach - from biobanking to precision medicine, A...
GetPersonalized! Estonian approach - from biobanking to precision medicine, A...
Sitra / Hyvinvointi
 
Skull base osteomyelitis
Skull base osteomyelitisSkull base osteomyelitis
Skull base osteomyelitiskamalaiims
 
Comorbidities and Clinical Features Related to Invasive Ventilatory Support a...
Comorbidities and Clinical Features Related to Invasive Ventilatory Support a...Comorbidities and Clinical Features Related to Invasive Ventilatory Support a...
Comorbidities and Clinical Features Related to Invasive Ventilatory Support a...
Institute for Clinical Research (ICR)
 
Professor Paul Heath on why we should be studying neonatal meningitis
Professor Paul Heath on why we should be studying neonatal meningitisProfessor Paul Heath on why we should be studying neonatal meningitis
Professor Paul Heath on why we should be studying neonatal meningitis
Meningitis Research Foundation
 

Similar to Dr Rodolfo villena (20)

Sickle Cell Disease: Newborn screening in France and the UK - Jacques Elion
Sickle Cell Disease: Newborn screening in France and the UK - Jacques ElionSickle Cell Disease: Newborn screening in France and the UK - Jacques Elion
Sickle Cell Disease: Newborn screening in France and the UK - Jacques Elion
 
Neonatal Meningitis
Neonatal MeningitisNeonatal Meningitis
Neonatal Meningitis
 
03_Challenge in diagnosis and management of dengue in adults_Dr. Terapong_11 ...
03_Challenge in diagnosis and management of dengue in adults_Dr. Terapong_11 ...03_Challenge in diagnosis and management of dengue in adults_Dr. Terapong_11 ...
03_Challenge in diagnosis and management of dengue in adults_Dr. Terapong_11 ...
 
Neonatal meningitis in the UK
Neonatal meningitis in the UKNeonatal meningitis in the UK
Neonatal meningitis in the UK
 
04.09.21 | Making Sense of the COVID-19 Data in Persons with HIV
04.09.21 | Making Sense of the COVID-19 Data in Persons with HIV04.09.21 | Making Sense of the COVID-19 Data in Persons with HIV
04.09.21 | Making Sense of the COVID-19 Data in Persons with HIV
 
ANAS UMAR INTERNAL DEFENCE SLIDES.pptx
ANAS UMAR INTERNAL DEFENCE SLIDES.pptxANAS UMAR INTERNAL DEFENCE SLIDES.pptx
ANAS UMAR INTERNAL DEFENCE SLIDES.pptx
 
DIAGNOSIS OF PEDIATRIC INFECTIOUS DISEASES
DIAGNOSIS OF PEDIATRIC INFECTIOUS DISEASESDIAGNOSIS OF PEDIATRIC INFECTIOUS DISEASES
DIAGNOSIS OF PEDIATRIC INFECTIOUS DISEASES
 
20180522 - universal health coverage from quantity to quality
20180522 - universal health coverage  from quantity to quality 20180522 - universal health coverage  from quantity to quality
20180522 - universal health coverage from quantity to quality
 
Prof Elizabeth Miller @ MRF's Meningitis & Septicaemia in Children & Adults 2015
Prof Elizabeth Miller @ MRF's Meningitis & Septicaemia in Children & Adults 2015Prof Elizabeth Miller @ MRF's Meningitis & Septicaemia in Children & Adults 2015
Prof Elizabeth Miller @ MRF's Meningitis & Septicaemia in Children & Adults 2015
 
Ahmed Samir Abd Elhafez.pptx
Ahmed Samir Abd Elhafez.pptxAhmed Samir Abd Elhafez.pptx
Ahmed Samir Abd Elhafez.pptx
 
05NTD 2022 - UPDATES IN VECTOR CONTROL IN MALAYSIA: What is new?
05NTD 2022 - UPDATES IN VECTOR CONTROL IN MALAYSIA:  What is new?05NTD 2022 - UPDATES IN VECTOR CONTROL IN MALAYSIA:  What is new?
05NTD 2022 - UPDATES IN VECTOR CONTROL IN MALAYSIA: What is new?
 
Mealesss Global Regional MR Elimination Overview
Mealesss Global Regional MR Elimination OverviewMealesss Global Regional MR Elimination Overview
Mealesss Global Regional MR Elimination Overview
 
Invasive meningococcal disease, Surveillance
Invasive meningococcal disease, Surveillance Invasive meningococcal disease, Surveillance
Invasive meningococcal disease, Surveillance
 
Impact of COVID-19 on High-risk Conditions and Associated Complications in a ...
Impact of COVID-19 on High-risk Conditions and Associated Complications in a ...Impact of COVID-19 on High-risk Conditions and Associated Complications in a ...
Impact of COVID-19 on High-risk Conditions and Associated Complications in a ...
 
AN MFA APPLICATION IN TUBERCULOSIS PREVALENCE ANALYSIS
AN MFA APPLICATION IN TUBERCULOSIS PREVALENCE ANALYSISAN MFA APPLICATION IN TUBERCULOSIS PREVALENCE ANALYSIS
AN MFA APPLICATION IN TUBERCULOSIS PREVALENCE ANALYSIS
 
Beyond safety mining and public health final
Beyond safety mining and public health finalBeyond safety mining and public health final
Beyond safety mining and public health final
 
GetPersonalized! Estonian approach - from biobanking to precision medicine, A...
GetPersonalized! Estonian approach - from biobanking to precision medicine, A...GetPersonalized! Estonian approach - from biobanking to precision medicine, A...
GetPersonalized! Estonian approach - from biobanking to precision medicine, A...
 
Skull base osteomyelitis
Skull base osteomyelitisSkull base osteomyelitis
Skull base osteomyelitis
 
Comorbidities and Clinical Features Related to Invasive Ventilatory Support a...
Comorbidities and Clinical Features Related to Invasive Ventilatory Support a...Comorbidities and Clinical Features Related to Invasive Ventilatory Support a...
Comorbidities and Clinical Features Related to Invasive Ventilatory Support a...
 
Professor Paul Heath on why we should be studying neonatal meningitis
Professor Paul Heath on why we should be studying neonatal meningitisProfessor Paul Heath on why we should be studying neonatal meningitis
Professor Paul Heath on why we should be studying neonatal meningitis
 

More from Meningitis Research Foundation

Dr william hanage
Dr william hanageDr william hanage
Sara katz
Sara katzSara katz
Camilla gladstone
Camilla gladstoneCamilla gladstone
Prof Adam Finn @ MRF's Meningitis and Septicaemia 2019
Prof Adam Finn @ MRF's Meningitis and Septicaemia 2019Prof Adam Finn @ MRF's Meningitis and Septicaemia 2019
Prof Adam Finn @ MRF's Meningitis and Septicaemia 2019
Meningitis Research Foundation
 
Prof Rob Heyderman
Prof Rob Heyderman Prof Rob Heyderman
Prof Rob Heyderman
Meningitis Research Foundation
 
Prof Andrew Pollard @ MRF's Meningitis and Septicaemia 2019
Prof Andrew Pollard @ MRF's Meningitis and Septicaemia 2019Prof Andrew Pollard @ MRF's Meningitis and Septicaemia 2019
Prof Andrew Pollard @ MRF's Meningitis and Septicaemia 2019
Meningitis Research Foundation
 
Prof Martin Maiden @ MRF's Meningitis and Septicaemia 2019
Prof Martin Maiden @ MRF's Meningitis and Septicaemia 2019 Prof Martin Maiden @ MRF's Meningitis and Septicaemia 2019
Prof Martin Maiden @ MRF's Meningitis and Septicaemia 2019
Meningitis Research Foundation
 
Prof Martin Antonio @ MRF's Meningitis and Septicaemia 2019
Prof Martin Antonio @ MRF's Meningitis and Septicaemia 2019 Prof Martin Antonio @ MRF's Meningitis and Septicaemia 2019
Prof Martin Antonio @ MRF's Meningitis and Septicaemia 2019
Meningitis Research Foundation
 
Prof Joy Lawn @ MRF's Meningitis and Septicaemia 2019
Prof Joy Lawn @ MRF's Meningitis and Septicaemia 2019Prof Joy Lawn @ MRF's Meningitis and Septicaemia 2019
Prof Joy Lawn @ MRF's Meningitis and Septicaemia 2019
Meningitis Research Foundation
 

More from Meningitis Research Foundation (9)

Dr william hanage
Dr william hanageDr william hanage
Dr william hanage
 
Sara katz
Sara katzSara katz
Sara katz
 
Camilla gladstone
Camilla gladstoneCamilla gladstone
Camilla gladstone
 
Prof Adam Finn @ MRF's Meningitis and Septicaemia 2019
Prof Adam Finn @ MRF's Meningitis and Septicaemia 2019Prof Adam Finn @ MRF's Meningitis and Septicaemia 2019
Prof Adam Finn @ MRF's Meningitis and Septicaemia 2019
 
Prof Rob Heyderman
Prof Rob Heyderman Prof Rob Heyderman
Prof Rob Heyderman
 
Prof Andrew Pollard @ MRF's Meningitis and Septicaemia 2019
Prof Andrew Pollard @ MRF's Meningitis and Septicaemia 2019Prof Andrew Pollard @ MRF's Meningitis and Septicaemia 2019
Prof Andrew Pollard @ MRF's Meningitis and Septicaemia 2019
 
Prof Martin Maiden @ MRF's Meningitis and Septicaemia 2019
Prof Martin Maiden @ MRF's Meningitis and Septicaemia 2019 Prof Martin Maiden @ MRF's Meningitis and Septicaemia 2019
Prof Martin Maiden @ MRF's Meningitis and Septicaemia 2019
 
Prof Martin Antonio @ MRF's Meningitis and Septicaemia 2019
Prof Martin Antonio @ MRF's Meningitis and Septicaemia 2019 Prof Martin Antonio @ MRF's Meningitis and Septicaemia 2019
Prof Martin Antonio @ MRF's Meningitis and Septicaemia 2019
 
Prof Joy Lawn @ MRF's Meningitis and Septicaemia 2019
Prof Joy Lawn @ MRF's Meningitis and Septicaemia 2019Prof Joy Lawn @ MRF's Meningitis and Septicaemia 2019
Prof Joy Lawn @ MRF's Meningitis and Septicaemia 2019
 

Recently uploaded

Myopia Management & Control Strategies.pptx
Myopia Management & Control Strategies.pptxMyopia Management & Control Strategies.pptx
Myopia Management & Control Strategies.pptx
RitonDeb1
 
Telehealth Psychology Building Trust with Clients.pptx
Telehealth Psychology Building Trust with Clients.pptxTelehealth Psychology Building Trust with Clients.pptx
Telehealth Psychology Building Trust with Clients.pptx
The Harvest Clinic
 
ICH Guidelines for Pharmacovigilance.pdf
ICH Guidelines for Pharmacovigilance.pdfICH Guidelines for Pharmacovigilance.pdf
ICH Guidelines for Pharmacovigilance.pdf
NEHA GUPTA
 
Global launch of the Healthy Ageing and Prevention Index 2nd wave – alongside...
Global launch of the Healthy Ageing and Prevention Index 2nd wave – alongside...Global launch of the Healthy Ageing and Prevention Index 2nd wave – alongside...
Global launch of the Healthy Ageing and Prevention Index 2nd wave – alongside...
ILC- UK
 
Yemen National Tuberculosis Program .ppt
Yemen National Tuberculosis Program .pptYemen National Tuberculosis Program .ppt
Yemen National Tuberculosis Program .ppt
Esam43
 
Medical Technology Tackles New Health Care Demand - Research Report - March 2...
Medical Technology Tackles New Health Care Demand - Research Report - March 2...Medical Technology Tackles New Health Care Demand - Research Report - March 2...
Medical Technology Tackles New Health Care Demand - Research Report - March 2...
pchutichetpong
 
Nursing Care of Client With Acute And Chronic Renal Failure.ppt
Nursing Care of Client With Acute And Chronic Renal Failure.pptNursing Care of Client With Acute And Chronic Renal Failure.ppt
Nursing Care of Client With Acute And Chronic Renal Failure.ppt
Rommel Luis III Israel
 
CHAPTER 1 SEMESTER V PREVENTIVE-PEDIATRICS.pdf
CHAPTER 1 SEMESTER V PREVENTIVE-PEDIATRICS.pdfCHAPTER 1 SEMESTER V PREVENTIVE-PEDIATRICS.pdf
CHAPTER 1 SEMESTER V PREVENTIVE-PEDIATRICS.pdf
Sachin Sharma
 
India Clinical Trials Market: Industry Size and Growth Trends [2030] Analyzed...
India Clinical Trials Market: Industry Size and Growth Trends [2030] Analyzed...India Clinical Trials Market: Industry Size and Growth Trends [2030] Analyzed...
India Clinical Trials Market: Industry Size and Growth Trends [2030] Analyzed...
Kumar Satyam
 
HEAT WAVE presented by priya bhojwani..pptx
HEAT WAVE presented by priya bhojwani..pptxHEAT WAVE presented by priya bhojwani..pptx
HEAT WAVE presented by priya bhojwani..pptx
priyabhojwani1200
 
.Metabolic.disordersYYSSSFFSSSSSSSSSSDDD
.Metabolic.disordersYYSSSFFSSSSSSSSSSDDD.Metabolic.disordersYYSSSFFSSSSSSSSSSDDD
.Metabolic.disordersYYSSSFFSSSSSSSSSSDDD
samahesh1
 
一比一原版纽约大学毕业证(NYU毕业证)成绩单留信认证
一比一原版纽约大学毕业证(NYU毕业证)成绩单留信认证一比一原版纽约大学毕业证(NYU毕业证)成绩单留信认证
一比一原版纽约大学毕业证(NYU毕业证)成绩单留信认证
o6ov5dqmf
 
Health Education on prevention of hypertension
Health Education on prevention of hypertensionHealth Education on prevention of hypertension
Health Education on prevention of hypertension
Radhika kulvi
 
Demystifying-Gene-Editing-The-Promise-and-Peril-of-CRISPR.pdf
Demystifying-Gene-Editing-The-Promise-and-Peril-of-CRISPR.pdfDemystifying-Gene-Editing-The-Promise-and-Peril-of-CRISPR.pdf
Demystifying-Gene-Editing-The-Promise-and-Peril-of-CRISPR.pdf
SasikiranMarri
 
Contact ME {89011**83002} Haridwar ℂall Girls By Full Service Call Girl In Ha...
Contact ME {89011**83002} Haridwar ℂall Girls By Full Service Call Girl In Ha...Contact ME {89011**83002} Haridwar ℂall Girls By Full Service Call Girl In Ha...
Contact ME {89011**83002} Haridwar ℂall Girls By Full Service Call Girl In Ha...
ranishasharma67
 
Jaipur ❤cALL gIRLS 89O1183002 ❤ℂall Girls IN JaiPuR ESCORT SERVICE
Jaipur ❤cALL gIRLS 89O1183002 ❤ℂall Girls IN JaiPuR ESCORT SERVICEJaipur ❤cALL gIRLS 89O1183002 ❤ℂall Girls IN JaiPuR ESCORT SERVICE
Jaipur ❤cALL gIRLS 89O1183002 ❤ℂall Girls IN JaiPuR ESCORT SERVICE
ranishasharma67
 
Deep Leg Vein Thrombosis (DVT): Meaning, Causes, Symptoms, Treatment, and Mor...
Deep Leg Vein Thrombosis (DVT): Meaning, Causes, Symptoms, Treatment, and Mor...Deep Leg Vein Thrombosis (DVT): Meaning, Causes, Symptoms, Treatment, and Mor...
Deep Leg Vein Thrombosis (DVT): Meaning, Causes, Symptoms, Treatment, and Mor...
The Lifesciences Magazine
 
POLYCYSTIC OVARIAN SYNDROME (PCOS)......
POLYCYSTIC OVARIAN SYNDROME (PCOS)......POLYCYSTIC OVARIAN SYNDROME (PCOS)......
POLYCYSTIC OVARIAN SYNDROME (PCOS)......
Ameena Kadar
 
Antibiotic Stewardship by Anushri Srivastava.pptx
Antibiotic Stewardship by Anushri Srivastava.pptxAntibiotic Stewardship by Anushri Srivastava.pptx
Antibiotic Stewardship by Anushri Srivastava.pptx
AnushriSrivastav
 
Navigating Challenges: Mental Health, Legislation, and the Prison System in B...
Navigating Challenges: Mental Health, Legislation, and the Prison System in B...Navigating Challenges: Mental Health, Legislation, and the Prison System in B...
Navigating Challenges: Mental Health, Legislation, and the Prison System in B...
Guillermo Rivera
 

Recently uploaded (20)

Myopia Management & Control Strategies.pptx
Myopia Management & Control Strategies.pptxMyopia Management & Control Strategies.pptx
Myopia Management & Control Strategies.pptx
 
Telehealth Psychology Building Trust with Clients.pptx
Telehealth Psychology Building Trust with Clients.pptxTelehealth Psychology Building Trust with Clients.pptx
Telehealth Psychology Building Trust with Clients.pptx
 
ICH Guidelines for Pharmacovigilance.pdf
ICH Guidelines for Pharmacovigilance.pdfICH Guidelines for Pharmacovigilance.pdf
ICH Guidelines for Pharmacovigilance.pdf
 
Global launch of the Healthy Ageing and Prevention Index 2nd wave – alongside...
Global launch of the Healthy Ageing and Prevention Index 2nd wave – alongside...Global launch of the Healthy Ageing and Prevention Index 2nd wave – alongside...
Global launch of the Healthy Ageing and Prevention Index 2nd wave – alongside...
 
Yemen National Tuberculosis Program .ppt
Yemen National Tuberculosis Program .pptYemen National Tuberculosis Program .ppt
Yemen National Tuberculosis Program .ppt
 
Medical Technology Tackles New Health Care Demand - Research Report - March 2...
Medical Technology Tackles New Health Care Demand - Research Report - March 2...Medical Technology Tackles New Health Care Demand - Research Report - March 2...
Medical Technology Tackles New Health Care Demand - Research Report - March 2...
 
Nursing Care of Client With Acute And Chronic Renal Failure.ppt
Nursing Care of Client With Acute And Chronic Renal Failure.pptNursing Care of Client With Acute And Chronic Renal Failure.ppt
Nursing Care of Client With Acute And Chronic Renal Failure.ppt
 
CHAPTER 1 SEMESTER V PREVENTIVE-PEDIATRICS.pdf
CHAPTER 1 SEMESTER V PREVENTIVE-PEDIATRICS.pdfCHAPTER 1 SEMESTER V PREVENTIVE-PEDIATRICS.pdf
CHAPTER 1 SEMESTER V PREVENTIVE-PEDIATRICS.pdf
 
India Clinical Trials Market: Industry Size and Growth Trends [2030] Analyzed...
India Clinical Trials Market: Industry Size and Growth Trends [2030] Analyzed...India Clinical Trials Market: Industry Size and Growth Trends [2030] Analyzed...
India Clinical Trials Market: Industry Size and Growth Trends [2030] Analyzed...
 
HEAT WAVE presented by priya bhojwani..pptx
HEAT WAVE presented by priya bhojwani..pptxHEAT WAVE presented by priya bhojwani..pptx
HEAT WAVE presented by priya bhojwani..pptx
 
.Metabolic.disordersYYSSSFFSSSSSSSSSSDDD
.Metabolic.disordersYYSSSFFSSSSSSSSSSDDD.Metabolic.disordersYYSSSFFSSSSSSSSSSDDD
.Metabolic.disordersYYSSSFFSSSSSSSSSSDDD
 
一比一原版纽约大学毕业证(NYU毕业证)成绩单留信认证
一比一原版纽约大学毕业证(NYU毕业证)成绩单留信认证一比一原版纽约大学毕业证(NYU毕业证)成绩单留信认证
一比一原版纽约大学毕业证(NYU毕业证)成绩单留信认证
 
Health Education on prevention of hypertension
Health Education on prevention of hypertensionHealth Education on prevention of hypertension
Health Education on prevention of hypertension
 
Demystifying-Gene-Editing-The-Promise-and-Peril-of-CRISPR.pdf
Demystifying-Gene-Editing-The-Promise-and-Peril-of-CRISPR.pdfDemystifying-Gene-Editing-The-Promise-and-Peril-of-CRISPR.pdf
Demystifying-Gene-Editing-The-Promise-and-Peril-of-CRISPR.pdf
 
Contact ME {89011**83002} Haridwar ℂall Girls By Full Service Call Girl In Ha...
Contact ME {89011**83002} Haridwar ℂall Girls By Full Service Call Girl In Ha...Contact ME {89011**83002} Haridwar ℂall Girls By Full Service Call Girl In Ha...
Contact ME {89011**83002} Haridwar ℂall Girls By Full Service Call Girl In Ha...
 
Jaipur ❤cALL gIRLS 89O1183002 ❤ℂall Girls IN JaiPuR ESCORT SERVICE
Jaipur ❤cALL gIRLS 89O1183002 ❤ℂall Girls IN JaiPuR ESCORT SERVICEJaipur ❤cALL gIRLS 89O1183002 ❤ℂall Girls IN JaiPuR ESCORT SERVICE
Jaipur ❤cALL gIRLS 89O1183002 ❤ℂall Girls IN JaiPuR ESCORT SERVICE
 
Deep Leg Vein Thrombosis (DVT): Meaning, Causes, Symptoms, Treatment, and Mor...
Deep Leg Vein Thrombosis (DVT): Meaning, Causes, Symptoms, Treatment, and Mor...Deep Leg Vein Thrombosis (DVT): Meaning, Causes, Symptoms, Treatment, and Mor...
Deep Leg Vein Thrombosis (DVT): Meaning, Causes, Symptoms, Treatment, and Mor...
 
POLYCYSTIC OVARIAN SYNDROME (PCOS)......
POLYCYSTIC OVARIAN SYNDROME (PCOS)......POLYCYSTIC OVARIAN SYNDROME (PCOS)......
POLYCYSTIC OVARIAN SYNDROME (PCOS)......
 
Antibiotic Stewardship by Anushri Srivastava.pptx
Antibiotic Stewardship by Anushri Srivastava.pptxAntibiotic Stewardship by Anushri Srivastava.pptx
Antibiotic Stewardship by Anushri Srivastava.pptx
 
Navigating Challenges: Mental Health, Legislation, and the Prison System in B...
Navigating Challenges: Mental Health, Legislation, and the Prison System in B...Navigating Challenges: Mental Health, Legislation, and the Prison System in B...
Navigating Challenges: Mental Health, Legislation, and the Prison System in B...
 

Dr Rodolfo villena

  • 1. “Sequelae at hospital discharge in 49 children with invasive meningococcal disease. Chile, 2009-2019”. november 2021 Cindy Arteta (1,2), Rodolfo Villena (1,3), María Elena Santolaya (1,2) 1. Faculty of Medicine Universidad de Chile, 2. Hospital de niños Dr Luis Calvo Mackenna 3. Hospital de niños Dr Exequiel González Cortés Contact: Rodolfo Villena. rvillena@uchile.cl
  • 2. • Introduction • “Defeating meningitis by 2030” is a goal of the World Health Organization • To address the sequelae is one of the pillar for it • Chilean study: overall IMD sequelae rate of 28% (MenB outbreak in 90s) • Objective • Describe the sequelae caused by IMD in pediatric patients • Methods • Cross-sectional study performed with medical records in two pediatric public hospitals in Santiago, Chile • Patients with diagnosis of IMD from 2009-2019 microbiologically confirmed were included • Bivariate analysis and logistic regression were performed “Sequelae at hospital discharge in 49 children with invasive meningococcal disease. Chile, 2009-2019”
  • 3. Table 1. Socio-demographic data of children with IMD, Chile, 2009-2019 79,5% 98% “Sequelae at hospital discharge in 49 children with invasive meningococcal disease. Chile, 2009-2019” Variables Total n=49 (%) Sequelae n=29 (%) 59% No sequelae n=20 (%) p value Age Median [IQR], months 9 [4-27] 8.0 [4-23] 12.0 [4-82] < 1 year old 28 (57.1) 18 (62.0) 10 (50.0) 0.40 1-4 years old 11 (22.4) 7 (24.1) 4 (20.0) 0.74 >5 years old 10 (20.4) 4 (13.7) 6 (30.0) 0.14 Gender Male 34 (69.3) 19 (65.5) 15 (75.0) 0.45 Socioeconomic status High 1 (2.0) 1 (3.4) 0 0.40 Middle 26 (53.0) 12 (41.3) 14 (70.0) 0.04 Low 22 (44.9) 16 (55.1) 6 (30.0) 0.08 Comorbidity Yes 16 (32.6) 9 (31.0) 7 (35.0) 0.76 Type of comorbidity Recurrent wheezing 9 (18.3) 5 (17.2) 4 (20.0) 0.78 Immunodeficiency 2 (4.0) 1 (3.4) 1 (5.0) 0.78 Prematurity 2 (4.0) 2 (6.9) 0 0.26 Neurological disease 1 (2.0) 0 1 (5.0) 0.22 Congenital cardiopathy 1 (2.0) 0 1 (5.0) 0.22 Obesity 4 (8.1) 3 (10.3) 1 (5.0) 0.52 Malnutrition 2 (4.0) 1 (3.4) 1 (5.0) 0.78 Results
  • 4. Univariate Associations Logistic Regression analysis Variable Total N 49 (%) Sequelae N 29 (%) No sequelae 20 (%) p value OR 95% CI Onset of symptoms before consulting (days) Median [IQR] 2.0 [1.0-4.0] 2.0 [1.0-3.0] 2.0 [1.0-3.0] 1 - - Number of medical visits 1 11 (22.4) 8 (27.5) 3 (15.0) 0.31 2 27 (55.1) 15 (51.7) 12 (60.0) 0.56 >3 11 (22.4) 6 (20.6) 5 (25.0) 0.67 Signs and symptoms Fever 49 (100) 29 (100) 20 (100) 1 Compromised general condition 36 (73.4) 23 (79.3) 13 (65.0) 0.26 0.28 (0.03 – 2.56) Shock 25 (51.0) 8 (27.5) 3 (15.0) 0.03 2.15 (0.49 – 9.41) Vomiting 31 (63.2) 16 (55.1) 15 (75.0) 0.01 17.06 (1.74 – 166.94) Diarrhea 14 (28.5) 8 (27.5) 6 (30.0) 0.84 1.62 (0.23 – 11.40) Abdominal pain 6 (12.2) 2 (6.9) 4 (20.0) 0.16 0.29 (0.04 – 1.80) Drowsiness/irritability 23 (46.9) 17 (58.6) 7 (35.0) 0.10 2.83 (0.39 – 20.44) Meningeal signs 21 (42.8) 17 (58.6) 4 (20.0) 0.007 0.04 (0.00 – 0.55) Neurological deficit 20 (40.8) 16 (55.1) 4 (20.0) 0.2 0.34 (0.07 – 1.56) Headache 14 (28.5) 10 (34.4) 4 (20.0) 0.27 1.09 (0.16 – 7.28) Seizures 3 (6.1) 2 (6.9) 1 (5.0) 0.78 - - Petechiae/rash 20 (40.8) 12 (41.3) 8 (40.0) 0.92 0.66 (0.12 – 3.48) Table 2. Clinical characteristics of invasive meningococcal disease by presents of sequelae in Chilean children during 2009-2019 Results “Sequelae at hospital discharge in 49 children with invasive meningococcal disease. Chile, 2009-2019”
  • 5. Univariate Associations Logistic Regression analysis Variable Total N 49 (%) Sequelae N 29 (%) No sequelae 20 (%) P value OR 95% CI Clinical diagnosis Meningitis + meningococcemia 19 (38.7) 17 (58.6) 2 (10.0) <0.001 12.75 (2.48 – 65.54) Bacteremia 10 (20.4) 1 (3.4) 9 (45.0) <0.001 0.007 (0.00 – 0.21) Septic arthritis 7 (14.2) 7 (24.1) 0 0.01 Meningitis 6 (12.2) 2 (6.9) 4 (20.0) 0.16 3.64 (0.31 – 41.65) Meningococcemia 5 (10.2) 0 5 (25.0) 0.06 - - Waterhouse Friderichsen Syndrome 2 (4.0) 2 (6.9) 0 0.23 - - Number of sequelae 1 19 (38.7) 19 (65.5) - 2 8 (16.3) 8 (27.5) - 3 2 (4.0) 2 (6.9) - Type of sequelae* Neurological disorders 19 (38.7) 19 (65.5) - Hearing loss 10 (20.0) 10 (34.4) - Osteoarticular 9 (18.3) 9 (31.0) - Skin scarring 3 (6.1) 3 (10.3) - Post discharge follow-up Yes 34 (69) 27 (93.1) 7 (35.0) <0.001 N. meningitidis serogroup B 17 (34.6) 11 (37.9) 6 (30.0) 0.61 W 30 (61.2) 16 (55.1) 14 (70.0) 0.29 Table 2. Clinical characteristics of invasive meningococcal disease by presents of sequelae in Chilean children during 2009-2019 Results “Sequelae at hospital discharge in 49 children with invasive meningococcal disease. Chile, 2009-2019”
  • 6. Table 3. Classification of sequelae in children with IMD “Sequelae at hospital discharge in 49 children with invasive meningococcal disease. Chile, 2009-2019” Type of sequelae Number of sequelae: 54 % Neurological disorders 32 59.2 Psychomotor developmental delay 12 22.2 Speech-language impairment 7 12.9 Seizures 5 9.2 Hypertonia/Hypotonia 5 9.2 Nerve damage 2 3.7 Attention deficit/ hyperactivity disorder 1 1.8 Hearing loss 10 18.5 Cochlear implant 2 3.7 Skin scarring 3 5.5 Osteoarticular 9 16.6 Movement limitation 6 11.1 Surgical debridement 2 3.7 Amputation 1 1.8 53% 27% 13% 7% 41% 18% 5% 36% Sequelae of meningococcal disease by serogroup in Chilean children Neurological disorders Hearing loss Skin scarring Osteoarticular W B p 0.03 Figure 1. Sequelae of meningococcal disease by serogroup in chilean children, 2009-2019 *
  • 7. “Sequelae at hospital discharge in 49 children with invasive meningococcal disease. Chile, 2009-2019” 2009-2013 2015-2019 Total 41 8 B 13 4 W 26 4 0 5 10 15 20 25 30 35 40 45 Cases Sequelae by serogroup and time interval in peadiatrics patients, Chile 2009-2019 p < 0.0001 * * *
  • 8. • Invasive meningococcal disease remains as a public health concern • A high rate of sequelae were found in pediatric patients in Chile (59%) • Focus in < 1 yoa, shock and meningeal signs at admission • Clinical manifestations: meningitis + meningococcemia • Neurological sequelae were the most prevalent • A multidisciplinary follow-up protocols to reduce their long-term impact must be urgently established as a priority to assess all children and their families with the aim to reduce the long-term consequences/impact of IMD Conclusions “Sequelae at hospital discharge in 49 children with invasive meningococcal disease. Chile, 2009-2019”
  • 9. “Sequelae at hospital discharge in 49 children with invasive meningococcal disease. Chile, 2009-2019”. november 2021 Cindy Arteta (1,2), Rodolfo Villena (1,3), María Elena Santolaya (1,2) 1. Faculty of Medicine Universidad de Chile, 2. Hospital de niños Dr Luis Calvo Mackenna 3. Hospital de niños Dr Exequiel González Cortés Contact: Rodolfo Villena. rvillena@uchile.cl